MA35841B1 - Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci - Google Patents
Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ciInfo
- Publication number
- MA35841B1 MA35841B1 MA37174A MA37174A MA35841B1 MA 35841 B1 MA35841 B1 MA 35841B1 MA 37174 A MA37174 A MA 37174A MA 37174 A MA37174 A MA 37174A MA 35841 B1 MA35841 B1 MA 35841B1
- Authority
- MA
- Morocco
- Prior art keywords
- derivatives
- preparing
- therapeutic use
- pyrazolopyridine
- pyrazolopyridine derivatives
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La présente invention concerne des dérivés de pyrazolopyridine inhibiteurs du fgf, représentés par la formule générale (i), un procédé d'élaboration de ces dérivés, et l'utilisation thérapeutique de ceux-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1161589A FR2984325A1 (fr) | 2011-12-14 | 2011-12-14 | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
PCT/EP2012/075328 WO2013087744A1 (fr) | 2011-12-14 | 2012-12-13 | Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci |
Publications (1)
Publication Number | Publication Date |
---|---|
MA35841B1 true MA35841B1 (fr) | 2014-12-01 |
Family
ID=47458918
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA37174A MA35841B1 (fr) | 2011-12-14 | 2014-07-02 | Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci |
Country Status (23)
Country | Link |
---|---|
US (2) | US20140350006A1 (fr) |
EP (1) | EP2791137B1 (fr) |
JP (2) | JP6214551B2 (fr) |
KR (1) | KR102012058B1 (fr) |
CN (2) | CN106317056B (fr) |
AU (1) | AU2012351712B2 (fr) |
BR (1) | BR112014014452A2 (fr) |
CA (1) | CA2857749A1 (fr) |
CL (1) | CL2014001539A1 (fr) |
CO (1) | CO7000778A2 (fr) |
DK (1) | DK2791137T3 (fr) |
EA (1) | EA027421B1 (fr) |
ES (1) | ES2719444T3 (fr) |
FR (1) | FR2984325A1 (fr) |
HK (1) | HK1198442A1 (fr) |
IL (1) | IL232906A (fr) |
MA (1) | MA35841B1 (fr) |
MX (1) | MX358422B (fr) |
PH (1) | PH12014501258A1 (fr) |
PL (1) | PL2791137T3 (fr) |
PT (1) | PT2791137T (fr) |
SG (2) | SG11201402851TA (fr) |
WO (1) | WO2013087744A1 (fr) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10138235B2 (en) | 2011-12-14 | 2018-11-27 | Sanofi | Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof |
FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
JP2016506914A (ja) | 2013-01-16 | 2016-03-07 | アンセルムInserm | 骨格成長遅延障害の予防または処置における使用のための、可溶性線維芽細胞増殖因子受容体3(fgr3)ポリペプチド |
AR094812A1 (es) | 2013-02-20 | 2015-08-26 | Eisai R&D Man Co Ltd | Derivado de piridina monocíclico como inhibidor del fgfr |
DK2970265T3 (en) | 2013-03-15 | 2018-10-01 | Plexxikon Inc | HETEROCYCLIC COMPOUNDS AND APPLICATIONS THEREOF |
US20140303121A1 (en) | 2013-03-15 | 2014-10-09 | Plexxikon Inc. | Heterocyclic compounds and uses thereof |
ES2691923T3 (es) * | 2013-06-14 | 2018-11-29 | Sanofi | Derivados de pirazolopiridina para uso en el tratamiento del cáncer de vejiga |
US9951047B2 (en) | 2014-08-18 | 2018-04-24 | Eisai R&D Management Co., Ltd. | Salt of monocyclic pyridine derivative and crystal thereof |
WO2017053604A1 (fr) | 2015-09-23 | 2017-03-30 | The Regents Of The University Of California | Composés pyrazolopyridines antiviraux puissants |
HUE058734T2 (hu) | 2016-07-07 | 2022-09-28 | Pfizer | Szolúbilis 3-as fibroblaszt növekedési faktor receptor (sFGFR3) polipeptidek és alkalmazásaik |
CA3079029A1 (fr) | 2017-10-13 | 2019-04-18 | Plexxikon Inc. | Formes solides d'un compose pour la modulation de kinases |
KR20200121823A (ko) * | 2018-02-16 | 2020-10-26 | 유씨비 바이오파마 에스알엘 | 약학적 6,5 헤테로비시클릭 고리 유도체 |
WO2019189241A1 (fr) | 2018-03-28 | 2019-10-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Agent thérapeutique pour le carcinome hépatocellulaire |
CN108774224B (zh) * | 2018-04-23 | 2020-10-30 | 浙江大学 | 吡唑并[3,4-b]吡啶类化合物及其制备方法和应用 |
CN110833556A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗肝纤维化的用途 |
WO2020178316A1 (fr) * | 2019-03-05 | 2020-09-10 | Aziende Chimiche Riunite Angelini Francesco - A.C.R.A.F. S.P.A. | Azaindazoles en 5 ou 7 utilisés comme inhibiteurs de bêta-lactamase |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2006050076A1 (fr) * | 2004-10-29 | 2006-05-11 | Janssen Pharmaceutica, N.V. | Composes de pyrrolyle fusionnes substitues par pyrimidinyle et utiles dans le traitement des troubles induits par la kinase |
DE102004061288A1 (de) * | 2004-12-14 | 2006-06-29 | Schering Ag | 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel |
RU2387653C2 (ru) * | 2005-05-16 | 2010-04-27 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназ |
US7541367B2 (en) * | 2005-05-31 | 2009-06-02 | Janssen Pharmaceutica, N.V. | 3-benzoimidazolyl-pyrazolopyridines useful in treating kinase disorders |
FR2889526B1 (fr) * | 2005-08-04 | 2012-02-17 | Aventis Pharma Sa | 7-aza-indazoles substitues, compositions les contenant, procede de fabrication et utilisation |
CA2662031A1 (fr) * | 2006-09-06 | 2008-03-13 | F. Hoffmann-La Roche Ag | Derives heteroaryles utilises en tant qu'inhibiteurs de proteine kinase |
KR20090031122A (ko) * | 2007-09-21 | 2009-03-25 | 주식회사 중외제약 | 인다졸 골격을 함유하는 화합물, 이의 제조방법 및 상기화합물을 함유하는 약제학적 조성물 |
CN101878221B (zh) * | 2007-11-30 | 2014-04-02 | 辉瑞有限公司 | 糖皮质激素受体激动剂 |
EP2379551A1 (fr) * | 2008-12-30 | 2011-10-26 | ArQule, Inc. | Composés de pyrazolo[3,4-b]pyridine substitués |
FR2951172B1 (fr) * | 2009-10-13 | 2014-09-26 | Pf Medicament | Derives pyrazolopyridines en tant qu'agent anticancereux |
EP3305073B1 (fr) * | 2009-12-21 | 2019-05-15 | Samumed, LLC | 1h-pyrazolo [3,4-b] pyridines et leurs utilisations thérapeutiques |
WO2012019954A1 (fr) * | 2010-08-12 | 2012-02-16 | Evotec (Uk) Ltd. | Composés pyrazolopyridine en tant qu'inhibiteurs de pde10a |
FR2984325A1 (fr) * | 2011-12-14 | 2013-06-21 | Sanofi Sa | Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique |
-
2011
- 2011-12-14 FR FR1161589A patent/FR2984325A1/fr active Pending
-
2012
- 2012-12-13 CN CN201610708994.1A patent/CN106317056B/zh active Active
- 2012-12-13 PT PT12808328T patent/PT2791137T/pt unknown
- 2012-12-13 ES ES12808328T patent/ES2719444T3/es active Active
- 2012-12-13 SG SG11201402851TA patent/SG11201402851TA/en unknown
- 2012-12-13 JP JP2014546500A patent/JP6214551B2/ja active Active
- 2012-12-13 US US14/364,420 patent/US20140350006A1/en not_active Abandoned
- 2012-12-13 SG SG10201510204QA patent/SG10201510204QA/en unknown
- 2012-12-13 CN CN201280069679.9A patent/CN104114555B/zh active Active
- 2012-12-13 DK DK12808328.4T patent/DK2791137T3/en active
- 2012-12-13 EA EA201491149A patent/EA027421B1/ru not_active IP Right Cessation
- 2012-12-13 PL PL12808328T patent/PL2791137T3/pl unknown
- 2012-12-13 MX MX2014007168A patent/MX358422B/es active IP Right Grant
- 2012-12-13 CA CA2857749A patent/CA2857749A1/fr not_active Abandoned
- 2012-12-13 EP EP12808328.4A patent/EP2791137B1/fr active Active
- 2012-12-13 KR KR1020147019030A patent/KR102012058B1/ko active IP Right Grant
- 2012-12-13 AU AU2012351712A patent/AU2012351712B2/en not_active Ceased
- 2012-12-13 WO PCT/EP2012/075328 patent/WO2013087744A1/fr active Application Filing
- 2012-12-13 BR BR112014014452A patent/BR112014014452A2/pt not_active Application Discontinuation
-
2014
- 2014-06-01 IL IL232906A patent/IL232906A/en active IP Right Grant
- 2014-06-04 PH PH12014501258A patent/PH12014501258A1/en unknown
- 2014-06-11 CL CL2014001539A patent/CL2014001539A1/es unknown
- 2014-07-02 MA MA37174A patent/MA35841B1/fr unknown
- 2014-07-10 CO CO14149160A patent/CO7000778A2/es unknown
- 2014-11-26 HK HK14111927A patent/HK1198442A1/xx unknown
-
2017
- 2017-03-07 US US15/451,970 patent/US20170231998A1/en not_active Abandoned
- 2017-07-07 JP JP2017133321A patent/JP2017206544A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA35841B1 (fr) | Dérivés de pyrazolopyridine, procédé d'élaboration de ces dérivés, et utilisation thérapeutique de ceux-ci | |
PH12017501426A1 (en) | Derivatives of betulin | |
MA35451B1 (fr) | Dérivés de pyrrolopyrimidine et de purine | |
IN2014CN00989A (fr) | ||
MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
CR20200286A (es) | DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294) | |
TN2012000401A1 (en) | Heterocyclic compound | |
TN2014000095A1 (en) | Pharmaceutical compositions | |
MX2011011733A (es) | Inhiibidores de dihidroorotato deshidrogenasa como compuestos virostaticos. | |
IN2012DN02139A (fr) | ||
GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
MX364400B (es) | Compuestos de tetraciclina. | |
PH12015502429A1 (en) | Dicarboxylic acid compound | |
IN2014DN05972A (fr) | ||
MA35196B1 (fr) | Dérivés de 2-amino-3-(inidazol-2-yl)-pyridine-4-one et utilisation de ceux-ci comme inhibiteurs de kinases associées au récepteur du vegf | |
CY1117011T1 (el) | Παραγωγα αζολιου | |
MY178583A (en) | Hydantoin derivative | |
MA37999B1 (fr) | Dérivés de macrolide, leur préparation et leur utilisation thérapeutique | |
BR112014015300A2 (pt) | derivado de hidroximetilfurfural | |
WO2012164055A3 (fr) | Nouveaux composés, leur synthèse et leur utilisation dans le traitement de la douleur | |
MX2013002656A (es) | Nuevo proceso. | |
MX2013014950A (es) | Compuestos para el tratamiento del cancer asociado con el papilomavirus humano. | |
UA79385U (ru) | Способ получения производных (((2-r-1,3-тиазол- 4-ил)метил)сульфанил)-азолов | |
MX345518B (es) | Compuestos analgesicos, metodos, y formulaciones. |